iajabmsIAJABMSIAJABMS2709-3298https://doi.org/10.47310/iajabms.2022.v03i01.001A Randomized Control Study for Comparison of Nasal Fluticasone and Combination Therapy of Montelukast and Levocetirizine in recovery status among Patients of Allergic RhinitisRishabhChadhaJeevankumarBackground: A limited number of randomized controlled trials available on comparison of efficacy of Nasal Fluticasone and Combination Therapy of Montelukast and Levocetirizine in allergic rhinitis patients. Therefore, we conducted the present study to compare the efficacy of intranasal Fluticasone and oral Levocetrizine and Montelukast therapy in treatment of allergic rhinitis. Material and Methods: The study was a prospective randomized, single blinded, comparative, parallel group study, with two intervention groups conducted at Civil Hospital Jogindernagar of Himachal Pradesh, India. A total of Fifty patients diagnosed with allergic rhinitis was randomly allocated to either  Group A receiving oral Montelukast and Levocetrizine or Group B receiving  Fluticasone propionate aqueous nasal spray and followed up for 6 weeks. Recovery status after 6 weeks was taken as primary outcome variables. Results: Among Group A , maximum patients 11(44%) were in age group of 31-40 years while in Group B maximum patients were in age group of 21-30 years.(p value 0.004) . Among both groups maximum patients were females i.e. in Group A , 14(56%)  patients were in  female while in Group B  17(68%) patients were females.(p value 0.561) Among both groups maximum patients  had symptoms of  Sneezing & Headache  i.e. in Group A , 16(64%)  patients had symptoms of  Sneezing & Headache  while in Group B  19 (76%) patients had symptoms of  Sneezing & Headache  .(p value 0.215) .Among Group A , Inferior turbinate hypertrophy was present in 14(56%) patients while in Group B Inferior turbinate hypertrophy was present in 18(72%)  patients.(p value 0.377) Among Group A , Recovery at 6 weeks was occurred in 9 (36%)  patients while in Group B Recovery at 6 weeks  was occurred  in 17(68 %) patients.(p value 0.046). Conclusion: Study concluded that there was statistically significant recovery at 6 weeks occurred in patients who were given intranasal fluticasone sparay as compared to patients who were given oral Montelukast and Levocetrizine tablets.